SCHEDULE: Lynx1 Capital Discloses 4.1% Stake in Precision BioSciences

Lynx1 Capital Management LP and Weston Nichols have reported a 4.1% beneficial ownership stake in Precision BioSciences Inc., totaling 993,913 shares of common stock.

Summary

• Lynx1 Capital Management LP and Weston Nichols have filed an Amendment No. 2 to Schedule 13G, disclosing their beneficial ownership in Precision BioSciences Inc.
• The reporting persons collectively beneficially own 993,913 shares of Precision BioSciences Inc. common stock.
• This ownership represents 4.1% of the company's outstanding common stock.
• The percentage is calculated based on 24,071,751 shares outstanding, which includes 10,815,000 shares from a recent offering and 13,256,751 shares outstanding as of October 29, 2025.
• The shares are held with shared voting and shared dispositive power.
• The acquisition was not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as moderately positive. The disclosure of a significant 4.1% stake by an investment manager suggests confidence in Precision BioSciences, although it is a routine regulatory filing and not an active investment decision announcement.

Positives

• A significant stake (4.1%) by an institutional investor like Lynx1 Capital Management LP could signal confidence in Precision BioSciences Inc.'s future prospects.
• The investment manager's continued holding of a substantial position suggests a long-term view.

Industry Context

StockSavvy.ai notes that institutional ownership disclosures, particularly from investment managers like Lynx1 Capital, are closely watched in the biotechnology sector. A significant stake can indicate a belief in the long-term potential of a company's pipeline or technology, especially for a company like Precision BioSciences which operates in a high-risk, high-reward industry.

Comparison to Industry Standards

• A 4.1% stake is a notable position for an institutional investor in a publicly traded company. While not a controlling stake, it signifies a substantial investment.
• For comparison, other biotech companies often see institutional ownership ranging from small positions to significant stakes, depending on their stage of development, market capitalization, and perceived risk/reward profile. For example, a similar-sized biotech firm might have several institutional investors holding 3-7% stakes, indicating a diversified institutional interest.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 4.1% stake may be viewed positively, potentially signaling validation of the company's value proposition.
• Management: Awareness of a substantial institutional holder may influence strategic decisions, though the filing explicitly states the acquisition is not for influencing control.

Key Dates

Recommendation

This filing is a routine disclosure of beneficial ownership by an institutional investor. While the 4.1% stake is notable and suggests confidence, it does not provide new operational or financial performance data to warrant a "buy" or "sell" recommendation. Investors should "hold" and await further fundamental updates from Precision BioSciences Inc. to make more informed decisions.

Keywords

Precision BioSciences, Lynx1 Capital Management, Weston Nichols, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Investment Management, Institutional Investor, SEC Filing